Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases
- PMID: 18833576
- PMCID: PMC2835546
- DOI: 10.1002/cncr.23930
Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases
Abstract
Background: The purpose of the current study was to characterize the outcomes of patients with metastatic triple-negative breast cancers, including the risk and clinical consequences of central nervous system (CNS) recurrence.
Methods: Using pharmacy and pathology records, a study group of 116 patients who were treated for metastatic triple-negative breast cancer at Dana-Farber Cancer Institute between January 2000 and June 2006 was identified.
Results: The median survival from time of metastatic diagnosis was 13.3 months. Sixteen patients (14%) were diagnosed with CNS involvement at the time of initial metastatic diagnosis; overall, 46% of patients were diagnosed with CNS metastases before death. The median survival after a diagnosis of CNS metastasis was 4.9 months. The age-adjusted and race-adjusted rate of death for patients whose first presentation included a CNS metastasis was 3.4 times (95% confidence interval, 1.9-6.1 times) that of patients without a CNS lesion at the time of first metastatic presentation. Of the 53 patients who developed brain metastases, only 3 patients were judged to have stable or responsive systemic disease in the face of progressive CNS disease at the last follow-up before death.
Conclusions: Triple-negative breast cancer is associated with poor survival after recurrence. CNS recurrence is common, but death as a direct consequence of CNS progression in the setting of controlled systemic disease is uncommon. Thus, it does not appear that the high rate of CNS involvement is because of a sanctuary effect, but rather is due to the lack of effective therapies in general for this aggressive subtype of breast cancer. New treatment strategies are needed.
Figures
Similar articles
-
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.Cancer. 2020 Jan 15;126(2):271-280. doi: 10.1002/cncr.32540. Epub 2019 Oct 3. Cancer. 2020. PMID: 31581314 Free PMC article.
-
Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.Arch Pathol Lab Med. 2014 Feb;138(2):175-81. doi: 10.5858/arpa.2012-0541-OA. Arch Pathol Lab Med. 2014. PMID: 24476516
-
[Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):381-4. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 21875471 Chinese.
-
Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?Clin Breast Cancer. 2020 Feb;20(1):e54-e64. doi: 10.1016/j.clbc.2019.06.007. Epub 2019 Jul 11. Clin Breast Cancer. 2020. PMID: 31447286 Review.
-
CNS metastases in breast cancer: old challenge, new frontiers.Clin Cancer Res. 2013 Dec 1;19(23):6404-18. doi: 10.1158/1078-0432.CCR-13-0790. Clin Cancer Res. 2013. PMID: 24298071 Free PMC article. Review.
Cited by
-
A novel cystathionine γ-lyase inhibitor, I194496, inhibits the growth and metastasis of human TNBC via downregulating multiple signaling pathways.Sci Rep. 2021 Apr 26;11(1):8963. doi: 10.1038/s41598-021-88355-9. Sci Rep. 2021. PMID: 33903672 Free PMC article.
-
Assessment of Brain Tumor Response: RANO and Its Offspring.Curr Treat Options Oncol. 2016 Jul;17(7):35. doi: 10.1007/s11864-016-0413-5. Curr Treat Options Oncol. 2016. PMID: 27262709 Review.
-
Updates in the management of brain metastases.Neuro Oncol. 2016 Aug;18(8):1043-65. doi: 10.1093/neuonc/now127. Neuro Oncol. 2016. PMID: 27382120 Free PMC article. Review.
-
Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer.Breast Cancer Res Treat. 2024 Apr;204(3):607-615. doi: 10.1007/s10549-023-07207-4. Epub 2024 Jan 19. Breast Cancer Res Treat. 2024. PMID: 38238552 Free PMC article.
-
BRCA1 mutation promotes sprouting angiogenesis in inflammatory cancer-associated fibroblast of triple-negative breast cancer.Cell Death Discov. 2024 Jan 5;10(1):5. doi: 10.1038/s41420-023-01768-5. Cell Death Discov. 2024. PMID: 38182557 Free PMC article.
References
-
- Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52. - PubMed
-
- Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74. - PubMed
-
- Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004;64:830–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous